Next Article in Journal
Size and Flexibility Define the Inhibition of the H3N2 Influenza Endonuclease Enzyme by Calix[n]arenes
Next Article in Special Issue
Complement Evasion in Borrelia spirochetes: Mechanisms and Opportunities for Intervention
Previous Article in Journal
Phenotypic and Genotypic Characteristics of Methicillin-Resistant Staphylococcus aureus (MRSA) Related to Persistent Endovascular Infection
Article Menu
Issue 2 (June) cover image

Export Article

Open AccessArticle

Disulfiram (Tetraethylthiuram Disulfide) in the Treatment of Lyme Disease and Babesiosis: Report of Experience in Three Cases

1
592 Route 22—Suite 1B, Pawling, NY 12564, USA
2
Northwell System, Northern Westchester Hospital, Mount Kisco, NY 10549, USA
3
Health Quest System, Sharon Hospital, Sharon, CT 06069, USA
Antibiotics 2019, 8(2), 72; https://doi.org/10.3390/antibiotics8020072
Received: 28 March 2019 / Revised: 20 April 2019 / Accepted: 25 May 2019 / Published: 30 May 2019
(This article belongs to the Special Issue Antibiotics Resistance of Borrelia)
  |  
PDF [248 KB, uploaded 30 May 2019]
  |  

Abstract

Three patients, each of whom had required intensive open-ended antimicrobial therapy for control of the symptoms of chronic relapsing neurological Lyme disease and relapsing babesiosis, were able to discontinue treatment and remain clinically well for periods of observation of 6–23 months following the completion of a finite course of treatment solely with disulfiram. One patient relapsed at six months and is being re-treated with disulfiram. View Full-Text
Keywords: Chronic Lyme disease; neuroborreliosis; Post-treatment Lyme disease syndrome (PTLDS); relapsing babesiosis; persistent infection; antibiotic treatment failure; disulfiram Chronic Lyme disease; neuroborreliosis; Post-treatment Lyme disease syndrome (PTLDS); relapsing babesiosis; persistent infection; antibiotic treatment failure; disulfiram
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material

SciFeed

Share & Cite This Article

MDPI and ACS Style

Liegner, K.B. Disulfiram (Tetraethylthiuram Disulfide) in the Treatment of Lyme Disease and Babesiosis: Report of Experience in Three Cases. Antibiotics 2019, 8, 72.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Antibiotics EISSN 2079-6382 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top